BioVersys AG (SIX: BIOV) announced that results from a Phase 2a clinical trial of its tuberculosis treatment have been published ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE